Where do we stand in applying the CHA 2 DS 2 -VASc score in clinical practice and how robust are the data on which the application of CHA 2 DS 2 -VASc score in the guidelines is currently based? There is little or no doubt of the need for OAC in patients with CHA 2 DS 2 -VASc scores of $2 and of the very low-risk status in those with a CHA 2 DS 2 -VASc score of 0. However, because there are large differences in estimates of stroke risk without antithrombotic treatment, the real focus of debate is in patients with a CHA 2 DS 2 -VASc score of 1. Thus, studies have shown a 3-fold difference in the annual stroke risk in AF patients with a CHA 2 DS 2 -VASc score of 1 and no OAC treatment, varying from 0.6% to >2.0% (7).
VOL. 65, NO. 14, 2015 Table w3 , the 1-year stroke rates were reduced from 1.46% (continuous treatment) to 1.18% when using only primary discharge diagnoses of ischemic stroke, and it was lowered further to 0.96% with full follow-up. This latter figure is very near the cutoff for starting non-vitamin K oral anticoagulants (6) . Because the quarantine period was only 14 days, it is unknown whether the rates would have been even lower, had a longer, more reasonable quarantine period of 4 weeks been used. 
